ENTPD1 and neoplasm: In the MOLP-8 xenograft model, we show a large increase in tumor macrophage infiltration upon treatment with SRF617 associated with SRF617 binding to CD39 on MOLP-8 cells and inhibition of CD39 ATPase activity.